DDD walks into Thursday's Q1 2026 earnings report having already handed its short sellers a brutal week.
The stock has surged 62% over the past month and gained 24% in Tuesday's session alone. Short interest is high — 31.9% of the free float is currently sold short, one of the most elevated readings in the market. But the borrow market tells a deceptively calm story. Cost to borrow has eased to 0.43% and drifted lower over the past month, suggesting the frenzy is not being driven by a borrow squeeze. Availability remains loose enough to support new short positions without friction. The ORTEX short score, at 81.3, places DDD in the top tier of the universe for bearish positioning pressure — yet that same crowded short base is now the fuel for the rally, as forced covering amplifies every up-tick.
Options traders are leaning heavily into the bullish move. The put/call ratio fell to 0.124 — near its 52-week low of 0.124 — and more than a standard deviation below its 20-day average of 0.131. That is as call-dominated a setup as this stock has seen all year, consistent with investors chasing upside exposure after the price surge rather than hedging against downside. The contrast with the stock's 52-week PCR high of 0.73 captures just how completely sentiment has flipped.
The analyst community is split and largely quiet. Coverage is thin: Cantor Fitzgerald carries an Overweight rating and held a $4.75 target as of late 2025, while Needham has reiterated Hold repeatedly without attaching a price target. The mean consensus target of $4.00 implies roughly 29% upside from current levels, though given the stock has moved 62% in a month, those targets are stale relative to the price action. The bull case rests on healthcare segment momentum — a 17% year-over-year growth in Personalized Healthcare and an 18% rise in FDA-approved parts manufacturing. Bears point to Q1 revenues running 8% below the prior year at $94.5 million, undershooting already-lowered expectations, with materials sales collapsing 23% on dental aligner inventory issues.
Insiders offer a muted counterpoint. Every insider transaction in the 90-day window was a sale — CEO Jeffrey Graves sold shares twice in April at prices around $1.87 and $1.98, well below current levels, alongside multiple EVPs. The trades were small in dollar terms, and the stock has since more than doubled their exit prices. Whether management reads the current price as an opportunity or an anomaly is the question Thursday's print is going to test.
See the live data behind this article on ORTEX.
Open DDD on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
